Literature DB >> 380801

Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.

R Catane, D D Von Hoff, D L Glaubiger, F M Muggia.   

Abstract

A review of the clinical data on azaserine, DON, and azotomycin reveals that these agents have limited but definite antitumor activity. All three drugs are analogs of L-glutamine and contain a diazo group. They have been studied as single agents in a wide variety of human malignancies and have also been included in trials using combination chemotherapy. Most of these studies were performed early in the history of clinical trials and, therefore, the method of reporting results and the evaluation criteria were quite different from those in use today. A renewed interest in these agents has been triggered by the remarkable activity of DON and azotomycin against human tumor lines implanted into nude mice. On the basis of this activity and the clinical data we have compiled, we feel that new clinical trials with these agents are warranted.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380801

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  20 in total

1.  Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase.

Authors:  P M Gómez-Fabre; J C Aledo; A Del Castillo-Olivares; F J Alonso; I Núñez De Castro; J A Campos; J Márquez
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

2.  The Cremeomycin Biosynthetic Gene Cluster Encodes a Pathway for Diazo Formation.

Authors:  Abraham J Waldman; Yakov Pechersky; Peng Wang; Jennifer X Wang; Emily P Balskus
Journal:  Chembiochem       Date:  2015-09-14       Impact factor: 3.164

Review 3.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

Review 4.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

Review 5.  Heteroatom-Heteroatom Bond Formation in Natural Product Biosynthesis.

Authors:  Abraham J Waldman; Tai L Ng; Peng Wang; Emily P Balskus
Journal:  Chem Rev       Date:  2017-04-04       Impact factor: 60.622

6.  Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.

Authors:  M P Sullivan; J A Nelson; S Feldman; B Van Nguyen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Phase I evaluation of AT-125 single dose every three weeks.

Authors:  S Taylor; R J Belt; U Joseph; C D Haas; B Hoogstraten
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 8.  Glutaminolysis and autophagy in cancer.

Authors:  Victor H Villar; Faten Merhi; Mojgan Djavaheri-Mergny; Raúl V Durán
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

9.  A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.

Authors:  Yicheng Chen; Yiqing Zhao; David L Bajor; Zhenghe Wang; J Eva Selfridge
Journal:  J Genet Genomics       Date:  2020-06-16       Impact factor: 4.275

10.  Discovery of a Diazo-Forming Enzyme in Cremeomycin Biosynthesis.

Authors:  Abraham J Waldman; Emily P Balskus
Journal:  J Org Chem       Date:  2018-05-29       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.